Sensorineural Hearing Loss Associated with Intrathecal Vancomycin

Klibanov, Olga M.; Filicko, Joanne; DeSimone, Joseph; Tice, David S

doi:10.1345/aph.1c145

Cited by 35 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intrathecal injection of drugs may cause pain, numbness and dysaesthesias, muscle spasm, weakness, hypertension, tachycardia, hypotension, syncope, transient unilateral ipsilateral facial weakness, major motor seizure, spinal seizure, transient bladder impairment,14 or even unusual sensorineural hearing loss 15. It is difficult to evaluate adverse effects from only one case report, but we did not see any.…”

Section: Discussionmentioning

confidence: 75%

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Wang

Zhang

et al. 2016

Eur J Hosp Pharm

View full text Add to dashboard Cite

The ubiquitous Acinetobacter baumannii is an important and troublesome pathogen of nosocomial infection. Multidrug-resistant A baumannii meningitis is very difficult to treat, usually with high mortality. The disease is generally associated with craniotomy, but rarely with lumbar puncture. However, in our case, a 45-year-old male construction worker suffered multidrug-resistant A baumannii meningitis associated with lumbar puncture. The patient responded poorly to the initial treatment with an intravenous infusion of tigecycline. However, later treatment with an intrathecal injection of tigecycline (concentration 1 mg/mL) at a dose of 10 mg every 12 hours proved to be highly efficacious. Thus, intrathecal injection of tigecycline should be seriously considered as a treatment for multidrug-resistant A baumannii meningitis.

show abstract

Section: Discussionmentioning

confidence: 75%

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Wang

Zhang

et al. 2016

Eur J Hosp Pharm

View full text Add to dashboard Cite

show abstract

“…Hearing decreased after the first dose and complete SNHL occurred after the second intrathecal dose. Hearing loss was irreversible (79). Intrathecal vancomycin may have entered the cochlea via the cochlear aqueduct, resulting in high concentrations of vancomycin in the cochlea leading to irreversible hearing loss.…”

Section: Vancomycin Clinical Studiesmentioning

confidence: 99%

Ototoxicity of Non-aminoglycoside Antibiotics

2021

View full text Add to dashboard Cite

It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.

show abstract

“…Ototoxicity and nephrotoxicity have been rarely reported with vancomycin (2), but most reports were from several decades ago when vancomycin was available in an unpurified form commonly referred to as ‘‘Mississippi mud.’’ Although the impurities found in this formulation are not proven ototoxins (36), the possibility exists. There have been several more recent case reports of ototoxicity (51,52). While auditory toxicity is rare with monotherapy, it is possible that concomitant receipt of other ototoxic medications may augment hearing loss.…”

Section: Patient Characteristics Influencing Dosingmentioning

confidence: 99%

Vancomycin Use in Patients Requiring Hemodialysis: A Literature Review

Pallotta

Manley

2007

Seminars in Dialysis

View full text Add to dashboard Cite

Vancomycin, a glycopeptide antibiotic, has remained a popular antimicrobial agent throughout the past five decades, and is often included in empiric antibiotic regimens. With gram-positive coverage, it has found a niche in the treatment of methicillin-resistant Staphylococcus aureus. Although vancomycin has been in existence for many years, questions remain regarding its use. New technologies and practice pattern changes have occurred over the years that altered vancomycin dosing in hemodialysis (HD) patients. Examples of these changes include increased resistance of many organisms, development of high flux HD filters, and reprocessing practices. This review provides a summary of the several concerns that exist in the dosing of vancomycin in HD patients today, and provides a summary table of intradialytic dosing regimens.

show abstract

Sensorineural Hearing Loss Associated with Intrathecal Vancomycin

Cited by 35 publications

References 17 publications

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Ototoxicity of Non-aminoglycoside Antibiotics

Vancomycin Use in Patients Requiring Hemodialysis: A Literature Review

Contact Info

Product

Resources

About